Core Insights - Arvinas has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, a second-generation PROTAC® androgen receptor degrader for prostate cancer [1][2] - The agreement includes a $150 million upfront payment and potential additional payments of up to $1.01 billion in development, regulatory, and commercial milestones, along with tiered royalties [1][2] - Novartis will handle all aspects of clinical development and commercialization for ARV-766 and the preclinical AR-V7 program [2] Group 1 - The partnership aims to accelerate the development of ARV-766 as a potential first-in-class treatment for prostate cancer patients [1][2] - ARV-766 is designed to selectively target and degrade the androgen receptor, showing preclinical activity in various tumor models, including those with AR mutations [4] - Arvinas utilizes its proprietary PROTAC® Discovery Engine platform to create therapies that degrade disease-causing proteins, with a focus on unmet medical needs [5] Group 2 - The transaction is subject to necessary consents or approvals, including antitrust considerations under the Hart-Scott-Rodino Antitrust Improvements Act [3] - Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Arvinas for this transaction [3]

Company Overview - Arvinas, Inc. (ARVN) is positioned well within the Medical - Biomedical and Genetics sector, which is currently experiencing positive earnings estimate revisions [1][2] - The company has seen a narrowing of loss estimates, with current quarter estimates improving from a loss of $1.64 per share to a loss of $1.54 per share, and current year estimates improving from a loss of $6.87 per share to a loss of $5.76 per share [2] Industry Insights - The Medical - Biomedical and Genetics industry has a Zacks Industry Rank of 73 out of more than 250 industries, indicating a strong position relative to other sectors [1] - The positive trends in the industry suggest that a rising tide could benefit multiple companies within this segment, including Arvinas [1] Investment Consideration - Arvinas is currently rated with a Zacks Rank 3 (Hold), which is considered a favorable signal for potential investors [2] - The combination of a strong industry ranking and solid estimate revisions makes Arvinas an intriguing choice for investors looking for opportunities in this sector [2]

NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas' PROTAC® protein degrader ...

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Biopharma Conference on Tuesday, March 12. Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat. A live audio webcast of the presen ...

Investors are always looking for stocks that are poised to beat at earnings season and Arvinas, Inc. (ARVN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Arvinas is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicat ...

Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -90.23%. A quarter ago, it was expected that this company would post a loss of $1.52 per share when it actually produced a loss of $1.18, delivering a surprise of 22.37%.Over the last four quarters, the company has surpassed ...

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include a new Phase 3 trial in combination with CDK4/6 inhibitors in the second-line setting and a new Phase 3 trial ...

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study leadin for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending further data and discussions with regulatory authorities, the expanded development plan for vepdegestrant will include ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 (State or other No.) 5 Sci ...

Shares of Arvinas, Inc. (ARVN) have gained 23.1% over the past four weeks to close the last trading session at $46.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $60.56 indicates a potential upside of 30.2%.The average comprises 16 short-term price targets ranging from a low of $20 to a high of $95, with a standard deviation of $22.41. While the lowest estimate indicates a ...